Where does Michel Detheux work?

Michel Detheux is Founder of iTeos Therapeutics and Chairman at Egle Tx and Chief Executive Officer & Board Director at Muna Therapeutics.

What companies did Michel Detheux found?

Michel Detheux founded iTeos Therapeutics.

Where did Michel Detheux go to school?

Michel Detheux studied at Solvay Brussels School of Economics and Management (CEPAC, Business/management); University of Glasgow (Post doc, Parasitology); Université catholique de Louvain (PhD, Biochemistry).

Michel Detheux

Founder

Chairman at Egle Tx · Chief Executive Officer & Board Director at Muna Therapeutics · Founder at iTeos Therapeutics

Denmark

FoundediTeos Therapeutics

About

Michel Detheux, Ph.D., is CEO of Muna Therapeutics, which develops treatments for neurodegenerative diseases. He co-founded iTeos Therapeutics and served as its President and CEO, overseeing its progression from preclinical stages to late-stage clinical development, including a NASDAQ IPO and a co-development and co-commercialization agreement with GlaxoSmithKline for the anti-TIGIT antibody belrestotug; earlier in his career he held roles at Ludwig Cancer Research and Ogeda (formerly Euroscreen). He currently serves as chairman and board member for Egle Therapeutics, Vor Bio, and MRM Health, holds a B.S. in Bioengineering and a Ph.D. in Biochemistry from the Catholic University of Louvain, and is the author of 51 peer-reviewed publications and inventor on 27 patent applications.

Chairman at Egle Tx

Intro paths

→

In turn, Michel can intro founders to Egle Tx's investors below.

Egle Tx's investors · 3

EQT Life SciencesLuxembourg · $11M – $66M checks Fund+Leuven · $5.5M – $16.5M checks JDRF T1D FundBoston

Chief Executive Officer & Board Director at Muna Therapeutics

Intro paths

→

In turn, Michel can intro founders to Muna Therapeutics's investors below.

Muna Therapeutics's investors · 4

Droia VenturesLeuven · $540K checks Sanofi VenturesCambridge · $5M checks Sofinnova PartnersParis · $540K – $27M checks V-Bio VenturesGhent · $270K – $2.2M checks

Co-founders at Muna Therapeutics

Rita Balice-GordonFounder

Joachim VilstrupHead of Protein Chemistry and Structural Biology; scientific co-founder

Founder at iTeos Therapeutics

Intro paths

→

In turn, Michel can intro founders to iTeos Therapeutics's investors below.

iTeos Therapeutics's investors · 2

MPM BioImpactBoston · $1M – $15M checks · since 2020 VIVES PartnersWavre · $108K – $7.6M checks · since 2020

Experience

Muna TherapeuticsCEO*current2026 — presentCopenhagen Metropolitan Area
MRM HealthChair of the Board of Directors*current2026 — presentGhent Metropolitan Area
BioForge Consulting SRLManaging Directorcurrent2026 — presentBelgium
Vor BioMember Board of Directorscurrent2025 — presentBoston, Massachusetts, United States
Egle TherapeuticsChair Of The Board Of Directorscurrent2024 — presentParis, France
iTeos Therapeutics SACo-founder, President & CEO2019 — 2026Watertown, Massachusetts, United States
iTeos Therapeutics SACo-founder & CEO*2012 — 2019Gosselies Belgium
ONA TherapeuticsChair Of The Board Of Directors2021 — 2024Barcelona, Catalonia, Spain
InnoskelChair Of The Board Of Directors2022 — 2023Biot, Provence-Alpes-Côte d'Azur, France
MG6A Bioconsulting SPRLFounder and Managing Director2012 — 2019Belgium
BioWinDirector of the Board*2016 — 2018Belgium
ImmuneHealthIndependent Board Member*2014 — 2016Gosselies Belgium
Ludwig Cancer ResearchDirector, Spin off project2010 — 2012
EuroscreenDirector Euroscreen FAST Business Unit2006 — 2010
EuroscreenManager, New Business Opportunities2005 — 2006
EuroscreenHead of Target Discovery1995 — 2004
University of GlasgowPost doctoral fellow1993 — 1994

Skills & more

Start-ups19Drug Discovery43Cancer Immunotherapy6Biotechnology36Business Development14R&D14Fundraising

Languages English · French

From Michel's professional profile.

Frequently asked questions

Who is Michel Detheux?: Michel Detheux, Ph.D., is CEO of Muna Therapeutics, which develops treatments for neurodegenerative diseases. He co-founded iTeos Therapeutics and served as its President and CEO, overseeing its progression from preclinical stages to late-stage clinical development, including a NASDAQ IPO and a co-development and co-commercialization agreement with GlaxoSmithKline for the anti-TIGIT antibody belrestotug; earlier in his career he held roles at Ludwig Cancer Research and Ogeda (formerly Euroscreen). He currently serves as chairman and board member for Egle Therapeutics, Vor Bio, and MRM Health, holds a B.S. in Bioengineering and a Ph.D. in Biochemistry from the Catholic University of Louvain, and is the author of 51 peer-reviewed publications and inventor on 27 patent applications.
Where does Michel Detheux work?: Michel Detheux is Founder of iTeos Therapeutics and Chairman at Egle Tx and Chief Executive Officer & Board Director at Muna Therapeutics.
What companies did Michel Detheux found?: Michel Detheux founded iTeos Therapeutics.
Where did Michel Detheux go to school?: Michel Detheux studied at Solvay Brussels School of Economics and Management (CEPAC, Business/management); University of Glasgow (Post doc, Parasitology); Université catholique de Louvain (PhD, Biochemistry).

Are you in our directory? — or find your own page and tap it there to see your paths to every investor.

Founder mafias

Université catholique de Louvain mafia33

Also came through, then founded or led a company.

François DerbaixEng.Founded Bewater Funds +2 Nicolas le JeuneBachelor of Business Administration (B.B.A.)Founded Courtyard +1 Benoît DeperBachelor of Science (BSc)Founded Aerospacelab +1 Julien StamatakisDoctor of Philosophy (PhD)Founded Attuneiot +1 Alexander KalisMaster's DegreeFounded East West Private Wealth Jean-Charles VelgeBachelor's DegreeFounded Qover

+ 26 more

University of Glasgow mafia30

Also came through, then founded or led a company.

Andrew AntosExchangeFounded Klarity +1 Aart de GeusHonorary PhDFounded Synopsys +1 Douglas J. JollyPh.D.Founded Abintus Bio +1 Rod MacGregorB. Sc.Founded GlassPoint Solar +1 Donald McClymontM.EngFounded indie Semiconductor +1 Robbie Th'ngBSc (Hons)Founded Unusual

+ 23 more

Solvay Brussels School of Economics and Management mafia20

Also came through, then founded or led a company.

Ofir EjnesBachelor's degreeFounded Elfie Fred DestinMAFounded Stride Pierre LagrangeMaster's degreeFounded mrs-wordsmith Quentin NickmansFinance & Business administrationFounded Aircall Jeroen MerchiersCommercial EngineerFounded Zazume Assem ChammahBachelor's degreeFounded Nexus

+ 13 more

iTeos Therapeutics mafia4

Also came through, then founded or led a company.

Detlev BiniszkiewiczDirectorFounded NextPoint Therapeutics Ansbert K. GadickeDirectorFounded Mpmcapital Jill DeSimoneIndependent Board DirectorFounded Indegene

Same school

Also attended Solvay Brussels School of Economics and Management102

Jeroen Van IseghemInvestment Analyst at Capricorn Venture Partners Olivier de DuveManaging Partner and Head of Investment Services at Inventures Investment Partners Ofir EjnesInvestor at FEBE Ventures Alexander CarlierInvestment Partner at Kharis Capital Victoire CarousPlatform Partner at Kharis Capital David JachirInvestor Relations & Business Development at Kharis Capital

+ 96 more

Also attended University of Glasgow102

Andreas SchropferHead of Finance at Brighteye Ventures Sarah MandersonLegal Director at Hoxton Ventures Kelsey BolanderAssociate — Business Ops & Partner Support at Energize Ventures Rob DesboroughGeneral Partner and Chair of Seraphim Space Accelerator at Seraphim Space Aida KhalilProgramme Associate at Seraphim Space Natalie JohnstonInvestment Principal at 4BIO Capital

+ 96 more

Also attended Université catholique de Louvain104

Iñigo López-HuertaCFO at Ysios Capital Charles de LiedekerkeInvestor at Inventures Investment Partners Paul VarassoPrincipal at Axeleo Capital Jérôme WittamerCo-founder and Managing Partner at Expon Capital Yves TrouveroyInvestment Partner at E-Capital Equity Management Vincent BrichardVenture Partner at EQT Life Sciences

+ 98 more

Shared employers

Also worked at iTeos Therapeutics SA5

Detlev BiniszkiewiczManaging Director at MPM BioImpact Jill DeSimoneDigital Pharma Advisor at Excelerate Health Ventures Chris BuyseBoard Member at Fund+Derek DiRoccoPartner at RA Capital David FeltquateAdvisor at RA Capital

Also worked at ONA Therapeutics8

Clara CampàsCo-founder and managing partner at Asabys Partners Guillem MasferrerPartner at Asabys Partners Montse VendrellPartner at Asabys Partners Joël Jean-MairetManaging Partner at Ysios Capital Pamela KleinVenture Partner at Ysios Capital Jonathan DupontAssociate at Mérieux Equity Partners

+ 2 more

Also worked at Ludwig Cancer Research8

Karen KnudsenAdvisor at Oncology Ventures Vincent BrichardVenture Partner at EQT Life Sciences Yann EchelardPartner, PhD at ORI Capital Amel TounsiInvestment Manager at Meusinvest (Noshaq)Khatereh AhmadiVenture Partner at XGEN Venture Jill WykoskyVenture Partner at RA Capital

+ 2 more

Also worked at University of Glasgow23

Natalie JohnstonInvestment Principal at 4BIO Capital John CampbellEIR at Delin Ventures Milana IdrisovaInvestment Analyst at Czech Founders VC Navas Ebin MuhammedCEO at Mars Growth Capital Anu MavilakandyManager, Intellectual Property Commercialisation at Swinburne Innovation Studio Harsh SnehanshuFounder at YourQuote

+ 17 more